These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30797268)

  • 1. Development of new drug-regimens against multidrug-resistant tuberculosis.
    Vasava MS; Nair SG; Rathwa SK; Patel DB; Patel HD
    Indian J Tuberc; 2019 Jan; 66(1):12-19. PubMed ID: 30797268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TB Alliance regimen development for multidrug-resistant tuberculosis.
    Murray S; Mendel C; Spigelman M
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):38-41. PubMed ID: 28240571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Present and future in the use of anti-tubercular drugs].
    Didilescu C; Craiova UM
    Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel drugs against tuberculosis: a clinician's perspective.
    Olaru ID; von Groote-Bidlingmaier F; Heyckendorf J; Yew WW; Lange C; Chang KC
    Eur Respir J; 2015 Apr; 45(4):1119-31. PubMed ID: 25431273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.
    Mesfin EA; Beyene D; Tesfaye A; Admasu A; Addise D; Amare M; Dagne B; Yaregal Z; Tesfaye E; Tessema B
    PLoS One; 2018; 13(6):e0197737. PubMed ID: 29864118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the treatment of tuberculosis.
    Zhang Y
    Clin Pharmacol Ther; 2007 Nov; 82(5):595-600. PubMed ID: 17898708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    Boeree MJ; Heinrich N; Aarnoutse R; Diacon AH; Dawson R; Rehal S; Kibiki GS; Churchyard G; Sanne I; Ntinginya NE; Minja LT; Hunt RD; Charalambous S; Hanekom M; Semvua HH; Mpagama SG; Manyama C; Mtafya B; Reither K; Wallis RS; Venter A; Narunsky K; Mekota A; Henne S; Colbers A; van Balen GP; Gillespie SH; Phillips PPJ; Hoelscher M;
    Lancet Infect Dis; 2017 Jan; 17(1):39-49. PubMed ID: 28100438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
    Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB
    Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
    Gao J; Ma Y; Du J; Zhu G; Tan S; Fu Y; Ma L; Zhang L; Liu F; Hu D; Zhang Y; Li X; Li L; Li Q
    BMC Pulm Med; 2016 Feb; 16():26. PubMed ID: 26846562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tuberculosis drug resistance in Ethiopia: systematic review.
    Weldegebreal S; Mebrahtu T
    Int J Tuberc Lung Dis; 2017 Jan; 21(1):18-22. PubMed ID: 28157460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia.
    Hamusse SD; Teshome D; Hussen MS; Demissie M; Lindtjørn B
    BMC Public Health; 2016 Jul; 16():593. PubMed ID: 27430266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.
    Nikonenko BV; Protopopova M; Samala R; Einck L; Nacy CA
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1563-5. PubMed ID: 17242141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculosis treatment in children: The changing landscape.
    Huynh J; Thwaites G; Marais BJ; Schaaf HS
    Paediatr Respir Rev; 2020 Nov; 36():33-43. PubMed ID: 32241748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
    Khan MY; Kinsara AJ; Osoba AO; Wali S; Samman Y; Memish Z
    Int J Antimicrob Agents; 2001 May; 17(5):415-8. PubMed ID: 11337231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015.
    Pradipta IS; Van't Boveneind-Vrubleuskaya N; Akkerman OW; Alffenaar JC; Hak E
    Antimicrob Resist Infect Control; 2019; 8():115. PubMed ID: 31338162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of drug-resistant tuberculosis in New Jersey from 1991 to 1995.
    Liu Z; Shilkret KL; Finelli L
    Int J Epidemiol; 1998 Feb; 27(1):121-6. PubMed ID: 9563705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current development and future prospects in chemotherapy of tuberculosis.
    Nuermberger EL; Spigelman MK; Yew WW
    Respirology; 2010 Jul; 15(5):764-78. PubMed ID: 20546189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
    Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.